Navigation Links
Cleveland Clinic study discovers new targets for treating inflammatory, autoimmune diseases
Date:10/7/2011

Friday, October 7, 2011, Cleveland: Researchers have discovered a cellular pathway that promotes inflammation in diseases like asthma, rheumatoid arthritis, psoriasis, inflammatory bowel disease, and multiple sclerosis. Understanding the details of this pathway may provide opportunities for tailored treatments of inflammatory and autoimmune diseases.

Discovery of this pathway was the work of an active collaboration between Xiaoxia Li, Ph.D., and Thomas Hamilton, Ph.D., Department Chair, both of the Department of Immunology at Lerner Research Institute of Cleveland Clinic.

Their publications in Nature Immunology, selected for a News and Views article in the same issue, portray how a protein molecule known as interleukin-17 (IL-17) spurs inflammation by recruiting specific white blood cells to sites of infection and injury, producing a strong, pathogenic response.

Being able to block this pathway may treat IL-17-induced inflammatory diseases. Molecular factors discovered by Li and Hamilton make this concept a potential strategy.

"We are excited by the possibilities that this new research opens up for developing improved therapeutics for these difficult diseases," Hamilton said.

"Being able to collaborate like this really expedites the science," Li added, "ultimately leading, we hope, to profound improvement for those suffering from these autoimmune and inflammatory conditions."


'/>"/>

Contact: Dan Doron
dorond@ccf.org
216-312-0428
Lerner Research Institute
Source:Eurekalert

Page: 1

Related biology news :

1. Ohio Third Frontier awards $2.5 million for imaging research in Cleveland
2. Cleveland researchers collaborate to launch Phase 1 clinical trial for new MS treatment
3. Radiation from Japan detected in Cleveland
4. Cleveland Clinic researchers honored for contributions to science and technology
5. Draft sequence of Neandertal genome wins the 2010 AAAS Newcomb Cleveland Prize, supported by Affymetrix
6. Cleveland Museum of Natural History scientist announces new horned dinosaur
7. Cleveland Clinic, CWRU dental researcher finds switch that turns on the spread of cancer
8. AMIA advises FDA on clinical decision support
9. Reports highlight the evolving role of clinical microbiology laboratories
10. New research validates clinical importance of leukemia stem cells
11. Clinical study shows young brains lack the wisdom of their elders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2016)... June 2, 2016 The Department of ... awarded the 44 million US Dollar project, for the ... Plates including Personalization, Enrolment, and IT Infrastructure , ... the production and implementation of Identity Management Solutions. Numerous renowned ... Decatur was selected for the most ...
(Date:5/20/2016)... May 20, 2016  VoiceIt is excited to ... VoicePass. By working together, VoiceIt and ... VoiceIt and VoicePass take slightly different approaches to ... both security and usability. ... this new partnership. "This marketing and ...
(Date:4/28/2016)... and BANGALORE, India , April ... EdgeVerve Systems, a product subsidiary of Infosys (NYSE: ... today announced a global partnership that will provide ... to use mobile banking and payment services.      ... a key innovation area for financial services, but it also ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... 27, 2016  Liquid Biotech USA ... of a Sponsored Research Agreement with The University ... (CTCs) from cancer patients.  The funding will be ... correlate with clinical outcomes in cancer patients undergoing ... then be employed to support the design of ...
(Date:6/24/2016)... ... , ... While the majority of commercial spectrophotometers and fluorometers use the z-dimension ... are higher end machines that use the more unconventional z-dimension of 20mm. Z-dimension ... bottom of the cuvette holder. , FireflySci has developed several Agilent flow cell ...
(Date:6/23/2016)... Mass. , June 23, 2016   ... development of novel compounds designed to target cancer ... napabucasin, has been granted Orphan Drug Designation from ... the treatment of gastric cancer, including gastroesophageal junction ... stemness inhibitor designed to inhibit cancer stemness pathways ...
(Date:6/23/2016)... ... June 23, 2016 , ... Charm Sciences, Inc. is ... has received AOAC Research Institute approval 061601. , “This is another AOAC-RI approval ... Bob Salter, Vice President of Regulatory and Industrial Affairs. “The Peel Plate methods ...
Breaking Biology Technology: